Labcorp® Plasma Complete™
A ctDNA liquid biopsy test for patients with advanced stage and metastatic solid tumors that evaluates 521 genes to inform the selection of targeted treatment options.
What is blood based liquid biopsy?1
As cells die, fragments of DNA are released into the bloodstream, known as 'cell-free DNA' (cfDNA). In the case of tumor cells, this becomes 'circulating tumor DNA (ctDNA).' Through the groundbreaking method of a 'liquid biopsy,' we can isolate cfDNA, including ctDNA, from peripheral blood, enabling the precise detection of genomic alterations to inform the selection of targeted treatment options.
What is Labcorp Plasma Complete?
Labcorp Plasma Complete is a 521-gene panel ctDNA liquid biopsy test for all advanced solid tumors, enabling the selection of targeted treatment options when tissue-based testing is not feasible. As a comprehensive NGS test, it delivers clear results for biomarkers associated with FDA-approved, guideline-driven, and investigational therapies.
Labcorp Plasma Complete test components2
Genomic alterations
SNVs and Indels: 521 genes*
Amplifications: 12 genes (CCND1, CDK4, CD274, EGFR, ERBB2 (HER2), FGF19, FGF3, FGF4, FGFR1, MDM2, MET, MYC)
Translocations: 12 genes (ALK, BRAF, ETV6, EWDR1, FGFR2, FGFR3, NTRK1, NTRK 2, NTRK 3, RET, ROS1, TMPRSS2)
*SNVs-single nucleotide variants; indels-insertions/deletions; MSI-microsatellite instability
Microsatellite instability status
Microsatellite instability assessment for immunotherapy decisions
Clinical trial identification
Geocoded clinical trials that may be considered for biomarker-directed treatment
Why choose Labcorp Plasma Complete
Expands treatment options
Maximize treatment options with an extensive panel that covers both established and emerging biomarkers
Streamlines experience
Integrate plasma-based genomic testing into your clinical workflows to enhance a comprehensive molecular assessment
Delivers timely results
Receive easy to read and comprehensive results
Examples of clinical scenarios to order Labcorp Plasma Complete3,4
-
obtaining tissue via biopsy is technically challenging
-
limited archived tumor tissue is available
-
rapid results are needed for treatment decisions
-
patient is progressing on current therapy
-
tissue biopsy test result is unavailable due to specimen quality or quantity insufficiency
Specimen requirements and storage
Specimen Requirements |
| Collect a total of 20 mL of whole blood into the 2 Streck BCT® tubes supplied in the Labcorp Oncology Liquid Biopsy Kit |
| Only the Labcorp Oncology Liquid Biopsy kit can be used for collection and shipping |
| Sample shipment to Labcorp Oncology must occur within 24 hours of blood draw |
Storage Instructions |
| Room temperature. Do not refrigerate or freeze. Keep out of direct sunlight |
Labcorp Plasma Complete resources
Labcorp Plasma Complete
-
High Laboratory Quality Standards
-
CLIA certified and CAP accredited
Medical affairs clinical support
Our team of pathologists and oncologists is available to support you and your patients through a centralized system.
Email: [email protected]
Phone: 800-781-1259
References:
- Filipska, M and Rosel, R. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment. Molecular Oncology. 2021; 15, 1667–1682. doi.org/10.1002/1878-0261.12983
- Verner EL, Jackson JB, Maddox C, et al. Analytical validation of the Labcorp Plasma Complete Test, a cell-free DNA comprehensive genomic profiling tool for precision oncology. J Mol Diagn. Published online 2025. doi:10.1016/j.jmoldx.2024.12.006
- Sabari JK, Offin M, Stephens D, et al. A prospective study of circulating tumor dna to guide matched targeted therapy in lung cancers. J Natl Cancer Inst. 2019;111(6):575-583. doi:10.1093/jnci/djy156
- García-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: Opportunities and challenges. Br J Cancer. 2022;127(4):592-602. doi:10.1038/s41416-022-01776-9